Availability of large and sophisticated libraries of diversified antibodies.
Highly advantageous intellectual property position; Affitech enjoys freedom to operate all aspects of phage display technology and maintains control of its proprietary phagemid systems.
Cost effective development and production of ‘designer’ antibodies in any format.
Right to use phage display-based antibody engineering methods already validated through alliances and collaborations.
Access to proprietary and innovative antibody applications, e.g., Troy-bodies and Pep-bodies.
Efficient decision making process.
